Introduction {#sec1}
============

Neurodegenerative disorders are a major challenge for medicine and public health due to demographic changes worldwide. The adeno-associated virus (AAV) vector, as a nonpathogenic viral particle, represents a powerful and promising therapeutic approach for human neurological diseases. As a result, several clinical trials applied to several human neurological genetic disorders (Sanfilippo type A and B, ClinicalTrials.gov: [NCT02053064](NCT02053064){#intref0010} and [NCT03300453](NCT03300453){#intref0015}, respectively; Batten disease, ClinicalTrials.gov: [NCT01414985](NCT01414985){#intref0020}; metachromatic leukodystrophy, ClinicalTrials.gov: [NCT01801709](NCT01801709){#intref0025}; and spinal muscular atrophy, ClinicalTrials.gov: [NCT02122952](NCT02122952){#intref0030}) were initiated by using AAVs. Direct brain parenchymal and intravenous deliveries are commonly used in clinical trials. In mice and large animal models, AAV9 was able to bypass the blood-brain barrier (BBB) and target predominantly neurons and spinal motor neurons (MNs), especially when the vector was administered intravenously at an early stage of life.[@bib1]^,^[@bib2] These AAV9 properties show spectacular outcomes in animal models[@bib3]^,^[@bib4] and clinically[@bib5] in the context of spinal muscular atrophy (SMA), which is a devastating MN disease. However, the translational feasibility of intravascular AAV administration is limited by the following: (1) the high doses required to achieve efficient vector diffusion and transgene expression in the CNS, which could lead to a potential off-target-based toxicity immunological response, and (2) the required challenging manufacturing process.[@bib6], [@bib7], [@bib8] Local intraparenchymal delivery overcomes the BBB. Indeed, efficient and long-term gene transfer in many brain structures has been described in several animal models after the intraparenchymal injection of the AAV vector in a restricted brain-injected region, such as in Parkinson's disease,[@bib9], [@bib10], [@bib11], [@bib12], [@bib13] or after multiple injection tracks in the brain, such as in lysosomal storage disease or more specifically, leukodystrophy.[@bib14], [@bib15], [@bib16], [@bib17] Several clinical trials have confirmed the high potential of this route of administration, with excellent safety and encouraging results in human patients for these applications.[@bib18]^,^[@bib19] However, intraparenchymal injection leads to a limited diffusion of the AAV vector, mainly in cells surrounding the injection site.[@bib20] Thus, this approach is difficult to apply in neurodegenerative diseases in which global CNS transduction in the brain and spinal cord is required.

In parallel, many research groups are developing cerebrospinal fluid (CSF)-based delivery via intracerebroventricular (ICV) injection, *cisterna magna* administration (ICM), or lumbar intrathecal puncture (LIT). These studies have successfully demonstrated that CSF administration of AAV is efficient to deliver genes into cells throughout the brain and in the entire spinal cord in rodents, cats, dogs, and nonhuman primates (NHPs).[@bib21], [@bib22], [@bib23], [@bib24], [@bib25] Among all serotypes tested, AAV9 and AAVrh10 show the highest neurotropism following intra-CSF delivery.[@bib26]^,^[@bib27] These promising results open up the field of gene therapy to numerous neurodegenerative diseases, giving a renewed hope to find a cure. However, the vast majority of the encouraging results in the preclinical model were obtained after administration of the therapeutic vector into the *cisterna magna*.[@bib28], [@bib29], [@bib30] Although this procedure is common and safe in veterinary medicine, it is highly risky in humans due to the proximity of vital brainstem centers. Due to this high-risk factor, ICM administration represents a nonprivileged method for the delivery of potential AAV medicine products in human trials.

To develop a translational therapeutic approach for human neurodegenerative diseases, we designed neurosurgical procedures in close collaboration with neurosurgeons. In the present study, we aimed to determine the most efficient and safe intra-CSF delivery for optimal gene transfer in an NHP model. Both tested approaches of administration, ICV and lumbar intrathecal puncture using a transitory catheter (LIT-KT), have previously been approved and performed in human clinics. As a second aim, we determined the most efficient serotype, between AAV9 and AAVrh10, to target and induce transgene expression in neuronal and glial cells across the entire CNS. We also assessed other variables critical for a translational approach, including biodistribution to peripheral organs and immunogenicity induced by the CSF delivery of AAV vectors.

Results {#sec2}
=======

Clinical Outcomes Following Intra-CSF Surgical Procedures {#sec2.1}
---------------------------------------------------------

To demonstrate the safety and reproducibility of both ICV and LIT-KT deliveries, the study was initiated with a significant set of animals (n = 2 and 4, respectively) using a contrast agent solution to monitor catheter positioning, control diffusion through the CNS, and monitor the intracranial pressure (ICP) to avoid intracranial hypertension.

Several studies, including ours, have demonstrated efficient transgene expression throughout the spinal cord after AAV9 delivery in the *cisterna magna* of rodents, cats, and NHPs.[@bib28], [@bib29], [@bib30], [@bib31], [@bib32] Suboccipital puncture is commonly used in veterinary medicine but is only rarely performed in humans, due to the high risk of encountering vessels during the procedure and the risk of hemorrhagic or ischemic complications. Therefore, we targeted the lateral ventricles, which have the advantage of being close to *cisterna magna* with a safer approach. A pilot study was first performed in 2 NHPs to set up the ICV surgical procedure. The correct placement in the lateral ventricle was verified under real-time radioscopic examination ([Figure 1](#fig1){ref-type="fig"}A). Contrast solution was visualized, showing a lateral ventricle that retained a radio-opaque solution, as demonstrated by yellow arrowheads ([Figure 1](#fig1){ref-type="fig"}A1). 10 s after administration, contrast agent was observed in the cervical ([Figure 1](#fig1){ref-type="fig"}A1), thoracic ([Figure 1](#fig1){ref-type="fig"}A2), and lumbar spinal cord ([Figure 1](#fig1){ref-type="fig"}A3) areas. Real-time video radioscopy was performed to illustrate the flow of contrast agent from the lateral ventricle to the cervical spinal cord ([Video S1](#mmc2){ref-type="supplementary-material"}). To limit CSF leakage from the injection site and therefore AAV vector leakage after lumbar puncture and to promote homogeneous distribution along the spinal cord, we optimized the surgical procedure by implementing LIT-KT. Intraspinal catheters have been used routinely for decades in various surgical and anesthesia settings.[@bib33] We used the same intrathecal catheter as used in pediatric medicine, and we introduced this catheter with an atraumatic SPROTTE cannula[@bib34] ([Figure 1](#fig1){ref-type="fig"}B3, inset). Under radioscopic control, the catheter was advanced until its tip was situated at the level of the last cervical vertebrae. We performed 3 deposits of 1 mL of PBS-contrast solution at the cervical thoracic and the lumbar level. A positive signal at radioscopy demonstrates the spreading of the solution into the *cisterna magna*, along the cervical spinal cord ([Figure 1](#fig1){ref-type="fig"}B1) and the thoracic spinal cord ([Figure 1](#fig1){ref-type="fig"}B2), as demonstrated by white arrowheads, and along the lumbar spinal cord ([Figure 1](#fig1){ref-type="fig"}B3). To determine whether intra-CSF administration was associated with ICP and to assess this safety aspect, we monitored intracranial pressure throughout the ICV and LIT-KT infusion in all NHPs ([Figure 1](#fig1){ref-type="fig"}C). The normal range for intracranial pressure is below 20 mmHg; above this limit, increased ICP occurs and may lead to potentially devastating CNS injuries.[@bib35] For the pressure monitoring of ICV administration, we injected NHP-01 and NHP-02 with 2.5 and 1 mL, respectively, with PBS-contrast agent solution. For NHP-01, the needle was inserted into the right lateral ventricle, and CSF pressure was measured at 9 mmHg. Then, 1.5 mL of PBS was injected, leading to 16 mmHg. Finally, an additional 1 mL of PBS was injected, leading to a CSF pressure of 21 mmHg. To determine whether intracranial hypertension is a transitory phenomenon, we measured the CSF pressure at 15 min post-injection and observed a restoration of the CSF pressure to 17 mmHg. For NHP-02, we removed approximately 1 mL of CSF by using spinal tap. Subsequent pressure measurements following CSF tap indicated a CSF pressure of 16 mmHg. Then, 1 mL of PBS was injected with a 0.1-mL step. CSF pressure was measured after the injection of 0.2, 0.3, 0.5, 0.7, and 1 mL of solution, leading to 17, 18, 20, 22, and 23 mmHg, respectively. Finally, at 15 min postadministration, we observed a decrease in CSF pressure to 17 mmHg.Figure 1Procedure, Contrast Agent Diffusion, and CSF Pressure Monitoring of the LIT-KT and ICV Administration in NHP(A) Placement of the needle into the right lateral ventricle was confirmed by fluoroscopic imaging and free-flowing cerebrospinal fluid. A representative image of contrast solution distribution into the right lateral ventricle (yellow arrow) at the time of intracerebroventricular injection and into the cervical spinal cord (A1) and 10 s after contrast solution administration into the thoracic (A2) and lumbar (A3) spinal cord. (B) Lumbar intrathecal puncture and SPROTTE cannula placement was performed into the lumbar intrathecal subarachnoid space of NHP. Fluoroscopic imaging and free-flowing CSF confirmed the position of the cannula (B3, inset). Then, the catheter was ascended to the cervical vertebrae under fluoroscopic monitoring, and 1 mL of contrast solution was injected (B1). The same procedure was performed for thoracic (B2) and lumbar contrast solution deposits (B3). White arrows indicate the signal from the contrast solution, and the green arrow indicates the needle used for CSF pressure monitoring. (C) Contrast solution was injected in NHPs following IT (n = 4; \#NHP-01--\#NHP-04) or ICV (n = 2; \#NHP-05 and \#NHP-06) administration, and the ICP was monitored in accordance with the intrathecal-injected volume. For LIT-KT-injected NHPs, ICP was monitored at the cannula placement (P0). Then, approximately 1 mL of CSF was removed for each NHP, and ICP was measured at the CSF drawing time point. Finally, ICP was analyzed at 0.5, 1, 1.5, 2, 2.5, and 3 mL of injected volume. An ultimate ICP measurement was performed 15 min after the end of contrast solution administration (+15 min time point). For ICV administration, \#NHP-05 received 0.5 mL of PBS, and ICP was measured after CSF drawing and just after contrast solution injection. \#NHP-06 received 2.5 mL of contrast solution, and ICP was analyzed at CSF drawing, 1.5 and 2.5 mL of injected volume, and 15 min after injection. Finally, \#NHP-07 received 1 mL of contrast solution, and ICP was monitored at CSF drawing, 0.2, 0.3, 0.5, 0.7, and 1 mL of injected volume, and 15 min after administration.

Video S1. ICV Contrast Solution Administration into Right Lateral Ventricle in NHPs

For LIT-KT pressure monitoring, NHP-03, -04, -05, and -06 were injected with 3 mL of PBS. All NHPs were subjected to CSF tap (approximately 1 mL), and CSF pressure measurements indicated a range of 5--6 mmHg for all NHPs. The CSF pressure assessment before spinal tap (performed in NHP-03 and NHP-06) indicated 13 and 10 mmHg, respectively, demonstrating the effect of spinal tap on CSF pressure. Then, CSF pressure was analyzed after the injection of 0.5, 1, 1.5, 2, 2.5, and 3 mL of PBS. The measurements in all NHPs indicated a constant increase in CSF pressure. It is important to mention that measurements not exceeding 20 mmHg, following IT administration, indicate no intracranial hypertension. Finally, measurements in NHP-05 and NHP-06 (animals that reached 20 mmHg, the highest point observed following LIT-KT injection of 3 mL of PBS) at 15 min postadministration demonstrated the decrease and restoration of CSF pressure. Based on this pilot experiment, we removed 1 mL of CSF and injected 0.5 and 3 mL through ICV and LIT-KT, respectively, for the following intra-CSF AAV administration experiments in NHPs. The magnetic resonance imaging (MRI) follow-up on the day of injection and at 3 days and 21 days post-injection did not show any abnormality (data not shown), as confirmed by neurobehavioral examination, which confirmed the safety profile of our ICV and LIT-KT administration approaches.

AAV9 Achieved Strong MNs and Consistent Brain Transduction Compared to the AAVrh10 Serotype {#sec2.2}
-------------------------------------------------------------------------------------------

We designed an experiment to compare the pattern of transgene expression in the NHP CNS following LIT-KT injection of both AAVrh10 (n = 2) and AAV9 (n = 4) expressing green fluorescent protein (GFP) ([Table 1](#tbl1){ref-type="table"}). A total of 2.5E+13 vector genomes (vg) in 3 mL of vector solution was injected into NHPs by the LIT-KT route of injection. For the group injected using AAVrh10-chicken β-actin promoter with cytomegalovirus enhancer (CBA)-GFP, no cell bodies expressed the GFP protein in the lumbar segment of the spinal cord. Only fibers expressing the GFP protein were found specifically in the dorsal horns ([Figure 2](#fig2){ref-type="fig"}A). In the thoracic segment, cell bodies and fibers expressed the GFP transgene, and at the cervical level, rare MNs showed GFP-positive signals ([Figure 2](#fig2){ref-type="fig"}A). Analysis of the animals injected with AAV9-CBA-GFP revealed strong GFP expression localized to ventral horns at all levels of the spinal cord ([Figure 2](#fig2){ref-type="fig"}A). Higher magnification in the ventral horns of cervical, thoracic, and lumbar spinal cord transversal sections revealed specific and robust GFP expression in MNs ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, longitudinal sections demonstrated an abundance of MNs expressing GFP throughout 5 mm of tissue ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B; [Figure 3](#fig3){ref-type="fig"}A, lower magnification). To identify the cell type expressing GFP in ventral horns, we performed immunofluorescence staining using ChAT, GFAP, Olig2, and Iba1 for MNs, astrocytes, oligodendrocytes, and microglial cells, respectively, in AAV9- and AAVrh10-injected NHPs. This experiment revealed the specific colocalization of GFP protein in MNs ([Figure 3](#fig3){ref-type="fig"}A). No GFP signal was observed in glial cells ([Figure S2](#mmc1){ref-type="supplementary-material"}). The quantification of MNs expressing GFP by using ChAT immunofluorescence was performed after checking the specificity of the GFP ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). GFP-positive MN quantification revealed 0.26% to 0.31% in the cervical segment, 0% in the thoracic segment, and 0% to 0.31% in the lumbar segment of the spinal cord for self-complementary (sc)AAVrh10-injected animals and 3.39% to 44.75% at the cervical level, 1.31% to 59.5% at the thoracic level, and 5.45% to 66.26% at the lumbar level of the spinal cord for AAV9-injected NHPs ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Since AAV9 seems to be the better serotype to target neuronal cells, we introduced a third group of injected NHPs (n = 2) using ICV administration to compare both the LIT-KT and ICV routes of injection in a large animal model. The volume of injection into the ventricle was smaller for safety consideration (0.5 mL of vector solution), leading to a dose of 4.5E+12 vg for each AAV9-CBA-GFP ICV-injected NHP ([Table 1](#tbl1){ref-type="table"}). 3 weeks after dosing, the animals were euthanized, and confocal fluorescence imaging analysis demonstrated the strong expression and localization of GFP at all levels of the spinal cord, especially in the ventral horns ([Figure 2](#fig2){ref-type="fig"}A). Quantification revealed a percentage of MNs expressing GFP of 3.3% to 20.1% in the cervical segment, 17.35% to 19.9% in the thoracic segment, and 16.65% to 65.45% in the lumbar segment of the spinal cord ([Figure S3](#mmc1){ref-type="supplementary-material"}D).Table 1Summary of Experimental DesignAnimal IdentificationAge (Years)Weight (kg)GenderRouteCapsidDose (vg)Volume (mL)Mac 133MLIT-KT102.50E+133Mac 233.1MLIT-KT102.50E+133Mac 333.4MLIT-KT92.50E+133Mac 42.53.1MLIT-KT92.50E+133Mac 533.7MLIT-KT92.50E+133Mac 62.53.4MLIT-KT92.50E+133Mac 723.2MICV94.50E+120.5Mac 822.7MICV94.50E+120.5[^1]Figure 2Effect of the Route of Administration and AAV Serotype on the GFP-Transgene Expression Profile(A) Spinal cord transduction following LIT-KT injection of the AAVrh10 and AAV9 serotypes or following AAV9 ICV injection. The representative whole spinal cord transversal section indicates rare/no transduction of the ventral horn gray matter for NHPs injected with AAVrh10, whereas transduction is observed primarily in the ventral horn for NHPs injected with LIT-KT and ICV AAV9. Green fluorescence illustrates the native GFP-positive signal and blue the nuclear 4′,6-diamidino-2-phenylindole (DAPI) signal. Hatched windows indicate regions of interest (ROIs) presented in the insets that show higher magnification of the ROI. Main image scale bar, 1 mm; inset scale bar, 100 μm. (B) Representative transduction throughout several brain regions following LIT-KT and ICV AAV9 administration. The green fluorescence signal illustrates the native GFP-positive signal. Scale bars, 150 μm.Figure 3Transduced Cell-Type Identification Throughout the Brain and Spinal Cord Following AAV9 Intra-CSF Delivery(A) AAV9 motor neuronal tropism was determined using ChAT (red channel) immunostaining in lumbar and thoracic spinal cord from NHPs injected by LIT-KT or ICV, respectively. Main images show Alexa 555/GFP merged fluorescence signals. Scale bars, 1 mm (left) and 100 μm (right). Insets show higher magnification on neurons harboring both fluorescence signals: GFP (top) and Alexa 555 (bottom) channels. Scale bar, 100 μm. (B) AAV9 cell-specific tropism was determined in brain representative sections from NHPs injected by LIT-KT and ICV. Brain tissues were immunolabeled using Olig2, GFAP, Iba1, and NeuN primaries for oligodendrocytes, astrocytes, microglial cells, and neuron phenotyping, respectively, and an Alexa 555 (red channel)-coupled secondary antibody was used for cell detection. GFP was determined by native GFP fluorescence signal imaging (green channel). Main images show Alexa 555/GFP merged fluorescence signals. Scale bars, 100 μm. Hatched windows indicate regions with GFP-positive cells, and insets show higher magnification on cells harboring both fluorescence signals: GFP (top) and Alexa 555 (bottom) channels. Scale bars, 25 μm.

Next, we determined the brain GFP expression pattern following LIT-KT AAVrh10 or AAV9 injection. For the AAVrh10 serotype, no GFP was found in any of the brain sections. Concerning the AAV9 serotype, patchy GFP expression was observed in several cell types across multiple regions. Analysis of GFP expression throughout several brain regions of the NHPs showed clustered transduced neuronal and glial cells in the frontal, parietal, and temporal cortices ([Figure 2](#fig2){ref-type="fig"}B). Immunofluorescence staining using neuronal and glial markers confirmed the presence of GFP-positive neurons, oligodendrocytes (in white matter), and astrocytes, whereas no microglial cells expressed GFP ([Figure 3](#fig3){ref-type="fig"}B). Deeper brain regions were analyzed. Rare neurons and astrocytes expressed GFP in the hippocampus ([Figure 2](#fig2){ref-type="fig"}B), putamen, hypothalamus, and body of caudate nucleus ([Figure S4](#mmc1){ref-type="supplementary-material"}). In the cerebellum, GFP was mainly expressed in white matter oligodendrocytes and rare neurons in the granular layer, and Purkinje cells were positive for the fluorescent protein ([Figure S4](#mmc1){ref-type="supplementary-material"}).

For NHPs injected with the AAV9-CBA-GFP vector using ICV administration, we found consistent GFP expression in the frontal lobe with a high number of GFP-positive neurons ([Figure 2](#fig2){ref-type="fig"}B). In the parietal and temporal cortices, the pattern of GFP expression was similar to that of LIT-KT-injected animals, with GFP-positive neurons and astrocytes ([Figure 2](#fig2){ref-type="fig"}B). Concerning the hippocampus, more neurons and glial cells expressed GFP. The GFP distribution and expression were similar to that observed in the cerebellum of LIT-KT-injected animals ([Figure 2](#fig2){ref-type="fig"}B); however, consistent glial GFP expression was observed close to the 4^th^ ventricle ([Figure S4](#mmc1){ref-type="supplementary-material"}). Finally, we found a similar pattern of GFP distribution in the hypothalamus, and rare neuronal and glial cells expressed GFP in the dorsolateral geniculate nucleus of the thalamus ([Figure S4](#mmc1){ref-type="supplementary-material"}).

The AAVrh10 Serotype Leads to Specific and Robust GFP Expression in Dorsal Root Ganglia (DRG) Neurons {#sec2.3}
-----------------------------------------------------------------------------------------------------

Following the consistent transduction achieved in the spinal MN of NHPs injected with the AAV9 serotype, we investigated whether AAVrh10 and AAV9 serotypes were able to transduce the peripheral nervous system, more specifically, DRG. Following LIT-KT AAVrh10 and AAV9, the majority of DRG expressing GFP was found at the cervical and lumbar levels. Thoracic DRG were less transduced. We found robust GFP expression in the soma of large-diameter neurons, mainly, and in fibers within all transduced DRG ([Figure 4](#fig4){ref-type="fig"}A). For AAV9 ICV-injected NHPs, the majority of DRG expressing GFP protein was observed distally to the injection site in thoracic and lumbar segments with a high number of GFP-positive, large-diameter neurons and some fibers ([Figure 4](#fig4){ref-type="fig"}A). Rare but GFP-positive, large-diameter neurons were found at the cervical site ([Figure 4](#fig4){ref-type="fig"}A). To characterize the type of sensory neurons transduced in DRG, we performed immunofluorescence staining against the substance P (SP) marker, a neuropeptide derived from preprotachinin. Involvement of SP in nociception and chronic pain syndrome is well established.[@bib36] SP immunostaining did not reveal any colocalization with GFP in the cervical and lumbar DRG for either AAV serotype ([Figure 4](#fig4){ref-type="fig"}B). These results suggest that AAVrh10 and AAV9 do not preferentially target sensitive neurons secreting SP. Finally, recent studies showed that systemic or *cisterna magna* AAV9 injection in NHP models triggered robust and mild axonal and neuronal degeneration, respectively, in DRG, characterized by cluster of differentiation (CD)3 T cells and mononuclear cells infiltrates.[@bib37]^,^[@bib38] Additionally, mice injected with AAV9-GFP by lumbar puncture displayed mononuclear aggregates and infiltrates and multifocal neuronal necrosis and loss in DRG.[@bib39] We therefore focused our attention on this safety aspect. Subsequent histopathological examination revealed multifocal mild mononuclear cell infiltration in thoracic and lumbar DRG for LIT-KT AAVrh10-injected Mac 1 and Mac 2 animals, respectively ([Figure S5](#mmc1){ref-type="supplementary-material"}). The same observations were found in LIT-KT AAV9-injected monkeys at the lumbar DRG site for Mac 4 and Mac 6 animals ([Figure S5](#mmc1){ref-type="supplementary-material"}). Moderate mononuclear cell infiltration was observed in cervical and lumbar DRG for Mac 3 animals ([Figure S5](#mmc1){ref-type="supplementary-material"}). Moreover, in DRG fibers from Mac 4, Mac 5, and Mac 6 animals, we also found mononuclear cell infiltration and digestion chambers that lead to myelin degradation ([Figure S5](#mmc1){ref-type="supplementary-material"}). Histopathological examination of the brain did not reveal any lesions.Figure 4GFP-Transgene Expression into the Peripheral Nervous System after Intra-CSF AAV9 or AAVrh10 Administration(A) Representative images demonstrate the native GFP fluorescence signal analyzed using confocal imaging in the cervical, thoracic, and lumbar DRG from NHPs injected with AAVrh10 and AAV9 by LIT-KT and AAV9 by ICV route of administration. DAPI was used for nuclear counterstaining. Scale bar, 200 μm. (B) SP immunostaining was performed in thoracic and lumbar DRG and revealed using an Alexa 555 (red channel) secondary antibody. The green channel displays the native GFP fluorescence. Cervical DRGs are not presented in this figure. Scale bar, 150 μm.

Intra-CSF AAV Administration Achieves Broad GFP Expression in the Skeletal and Respiratory Muscles and Heart and Moderate GFP Expression in the Liver {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether intra-CSF delivery leads to peripheral organ targeting, we examined several anatomically distinct skeletal and respiratory muscles, the heart, and the liver of all NHPs included in this study. Diaphragm, gastrocnemius, and triceps brachii muscles were collected to compare and quantify GFP expression in muscle fibers. Interestingly, we found a high number of diaphragmatic muscle fibers expressing GFP protein following LIT-KT injection of both serotypes ([Figure 5](#fig5){ref-type="fig"}A). However, quantification revealed a higher number of GFP-expressing diaphragmatic muscle fibers with the AAV9 serotype (≈54.2% of total fibers) than with the AAVrh10 serotype (≈33.3% of total fibers) ([Figure 5](#fig5){ref-type="fig"}B). Surprisingly, ICV administration of scAAV9-CBA-GFP achieved diaphragm muscle transduction ([Figure 5](#fig5){ref-type="fig"}A), but a lower amount, approximately 15% of total fibers, was transduced ([Figure 5](#fig5){ref-type="fig"}B). Analysis of the gastrocnemius muscle demonstrated a higher percentage of transduced fibers for AAV9 LIT-KT (≈36.5%) and AAV9 ICV (≈32.2%) than for AAVrh10 LIT-KT, which led to approximately 22.7% of transduced muscle fibers ([Figures 5](#fig5){ref-type="fig"}A and 5B). Concerning the triceps brachii muscle, the AAVrh10 serotype achieved a higher percentage of fiber transduction than did the AAV9 serotype (≈33.3% and 19.7%, respectively). Only 1/4 of the AAV9 LIT-KT-injected NHPs reached 38.9% of transduced muscle fibers of the triceps brachii. AAV9 ICV administration led to limited muscle fiber transduction, since approximately 2.7% of total muscle fibers were GFP positive ([Figure 5](#fig5){ref-type="fig"}B). Cardiac tissue analysis demonstrated moderate GFP expression by using LIT-KT AAV9 administration, whereas LIT-KT AAVrh10 and ICV AAV9 led to poor GFP expression ([Figures 5](#fig5){ref-type="fig"}A and 5C). Finally, analysis of the liver demonstrated an equivalent proportion of GFP expression throughout all groups ([Figures 5](#fig5){ref-type="fig"}A and 5C). Regarding the limited number of animals used in this study, it was not possible to make a direct correlation between the serotype and/or the route of administration and the muscle fibers, heart, and liver transgene expression. Finally, we performed a qualitative analysis of peripheral organs in all AAV-injected groups. The fluorescence analysis by confocal microscopy revealed GFP expression into the thymus, spleen, kidney, jejunum, and testis; however, no GFP transgene was observed into the lung in all AAV-injected groups ([Figure S6](#mmc1){ref-type="supplementary-material"}). Taken together, these results suggested a consistent escape of AAV particles from the CSF to peripheral organs after intra-CSF administration that allowed transgene expression in NHPs.Figure 5Muscle and Peripheral Organs Targeting Following Intra-CSF AAV9 and AAVrh10(A) GFP expression profiles in NHP diaphragm, gastrocnemius, triceps brachii muscles, heart, and liver following AAVrh10-CBA-GFP LIT-KT delivery and AAV9-CBA-GFP administration via LIT-KT and ICV routes. (a--l) GFP fluorescence, green; wheat germ agglutinin (WGA)-Alexa 555 fluorescent labeling, red. Scale bars, 50 μm. (Am--o) GFP fluorescence, green; unmixed autofluorescence, red. Scale bar, 25 μm. (B) % GFP-positive muscle fibers quantified from diaphragm, gastrocnemius, and triceps brachii muscle sections of NHPs injected with AAVrh10-CBA-GFP LIT-KT (n = 2) and of NHPs injected with AAV9-CBA-GFP administration via the LIT-KT route (n = 4) and ICV delivery (n = 2). Data represented on the graph corresponded to at least 1,000 muscle fibers. (C) % GFP-positive area quantified from heart and liver sections of NHPs injected with AAVrh10-CBA-GFP LIT-KT delivery (n = 2) and of NHPs injected with AAV9-CBA-GFP administration via LIT-KT (n = 4) and ICV routes (n = 2). Data represented on the graph corresponded at least 2 mm^2^ of tissue area investigated, with approximately 1,000 cells explored.

Escape of AAV Particles from the CNS to the Peripheral Compartment Is a Rapid Phenomenon Mediated by Blood Circulation {#sec2.5}
----------------------------------------------------------------------------------------------------------------------

Since AAV9 and AAVrh10 allowed transgene expression in peripheral organs, we focused our attention on the AAV distribution throughout CSF and serum over a 24-h period to determine the dynamics of viral particles following intra-CSF administration. NHPs injected by AAVrh10 LIT-KT, AAV9 LIT-KT, and AAV9 ICV were subjected to blood and CSF drawing after AAV dosing. As a baseline control, viral particle detection was performed before AAV dosing in both fluids. Analysis of the CSF revealed rare detection of viral particles at 7 and 19 days following dosing in all injected NHPs in this study ([Figure 6](#fig6){ref-type="fig"}A). Serum analysis demonstrated the presence of viral particles at 1 h following dosing (day 0 \[D0\] +1 h), which represented an average of approximately 4.85%, 6.99%, and 4.58% of the total injected dose for AAVrh10 LIT-KT, AAV9 LIT-KT, and AAV9 ICV, respectively. It is important to note that this time point was higher in terms of concentration in peripheral blood, since we found 1.62%, 5.07%, and 1.30% of the total injected dose for AAVrh10 LIT-KT, AAV9 LIT-KT, and AAV9 ICV, respectively, at 3 days postdosing ([Figure 6](#fig6){ref-type="fig"}B). Finally, at 7, 10, and 19 days post-injection, the AAV serum concentration was approximately zero ([Figure 6](#fig6){ref-type="fig"}B). These results suggest a rapid distribution to peripheral organs of AAV viral particles after intra-CSF dosing.Figure 6AAV9 and AAVrh10 Particles Shedding in the Serum and CSF(A and B) AAV viral genome shedding was analyzed at time points 0 (before injection), 7, and 19 days after vector administration in NHPs CSF (A) and in serum at time points 0, 1 h, and 3, 7, 10 and 19 days post-injection (B). DNA viral genome increase after AAV LIT-KT and ICV injection showed the presence of AAV particles in serum and CSF and was expressed as percentage of injected total dose.

Since we demonstrated the presence of circulating AAV in the bloodstream, we examined whether AAV particles injected by the intra-CSF route could trigger a peripheral immune response against the serotype capsid and GFP transgene. To this end, serum and CSF samples were analyzed for the prevalence of neutralizing factors (NFs) against both serotypes used in this study. We also evaluated whether NF formation was dependent on the route of injection. Baseline serum samples revealed an NF titer less than 1/10 for all NHPs, except Mac 6, which displayed a titer of 1/100. At 3 days post-AAV administration, all animals presented an NF titer less than 1/10; however, 5/6 AAV9-injected animals showed a significant increase (≥1/1,000) in the NF serum titer at 1 week post-injection. At 10 days post-CSF dosing and at sacrifice, all animals in this study were significantly positive for NF in the serum ([Table 2](#tbl2){ref-type="table"}). Interestingly, evaluation of the NF titer in the CSF revealed no change compared to baseline in 5/8 NHPs; however, 3/8 animals displayed a 1/100 neutralizing antibody (NAb) titer in CSF ([Table 2](#tbl2){ref-type="table"}). Concerning the GFP transgene, lymphocyte T CD8^+^ response monitoring by interferon gamma ELISpot detection demonstrated a cellular immune response against the GFP protein for Mac 1, Mac 3, and Mac 4 animals ([Table S1](#mmc1){ref-type="supplementary-material"}). Quantification of the titer of antibodies against GFP in serum revealed an increase in concentration for Mac 1, Mac 3, Mac 4, and Mac 5 animals ([Table S1](#mmc1){ref-type="supplementary-material"}). Interestingly, this result was closely correlated with the cellular immune response against the GFP transgene. However, in our study, we were unable to make a correlation between the route of administration and the anti-GFP antibody titer because of the limited number of injected NHPs per group.Table 2AAV Neutralizing Factor Titer in the Serum and CSFSerum NF TiterCSF NF TiterAnimal IdentificationRouteCapsidBaselined0d3d7d10dEuthd0dEuthMac 1LIT-KT10\<1/10\<1/10NANANA1/10,000\<1/10\<1/10Mac 2LIT-KT10\<1/10NA\<1/10NA1/10,0001/1,000\<1/10\<1/10Mac 3LIT-KT9NANA\<1/101/1,0001/1,0001/10,000NA1/100Mac 4LIT-KT9\<1/10NANA1/10,0001/10,0001/10,000\<1/101/100Mac 5LIT-KT9NANA\<1/101/1,0001/1,0001/1,000\<1/10\<1/10Mac 6LIT-KT91/100NA\<1/10\<1/101/1,0001/1,000\<1/10\<1/10Mac 7ICV9\<1/10NA\<1/101/1,0001/1,0001/1,000NA1/100Mac 8ICV9\<1/10NA\<1/101/1,0001/1,0001/1,000\<1/10\<1/10[^2]

Discussion {#sec3}
==========

We and others have demonstrated the efficiency of spinal cord and brain targeting following AAV administration by using suboccipital (*cisterna magna*) or single lumbar puncture in rodents and large animal models.[@bib24]^,^[@bib28]^,^[@bib30] However, intra-*cisterna magna* delivery may not be clinically translatable, and the lumbar intrathecal route allows moderate transgene expression in the upper part of the spinal cord and in the brain.[@bib24] The ICV route was previously used in a large animal model for AAV delivery into the CNS, demonstrating therapeutic benefits and a good safety profile.[@bib29] However, to our knowledge, no groups have developed ICV delivery in NHPs. Under the supervision of neurosurgeons in a large animal model facility equipped with material used in the human clinic, we demonstrated that injection into the lateral ventricle of NHPs was well tolerated. No adverse event was reported in clinical-outcome monitoring assessed by global activities, fine motor functions, ocular activities, and attention. Safety consideration regarding CNS surgical procedure includes ICP. Since CSF homeostasis is highly sensitive, and positioning of the body or fluid injection can lead to the increase in the ICP,[@bib40] we demonstrate robust tolerance after CSF injection of recombinant (r)AAV, suggesting that both neurosurgical procedures could be translated to patients.

To date, no studies have compared AAVrh10 and AAV9 serotypes. We previously demonstrated that AAVrh10 led to moderate MN targeting compared to AAV9 by using an IT route in mice.[@bib24] We also demonstrated that compared to the AAVrh10 serotype, AAV9 achieved the best molecular, histologic, and phenotypic correction of Pompe disease in the CNS of a mouse model.[@bib30] Previous studies reported in a marmoset primate model that a single lumbar injection of AAVrh10-CBA-GFP, respectively, at a dose of 2.7E+12 vg or of 6E+12 vg/kg led to efficient MN transduction along the spinal cord.[@bib41] Recently, the same group reported that in *cynomolgus macaque*, lumbar intrathecal delivery of an AAVrh10-polymerase III-microRNA (miR)-GFP optimized using a catheter extended to the low thoracic region at a dose of 3.5E+13 vg led to profound superoxide dismutase 1 (SOD1) silencing and consistent GFP expression in MNs in the cervical, thoracic, and lumbar areas of the spinal cord and in the brain.[@bib42] An inferior dose (2.5E+13 vg per NHP) was injected by LIT-KT administration in the present study. The pattern of transduction highlighted poor GFP expression in MNs along the spinal cord and no GFP expression in the brain of animals injected with AAVrh10-CBA-GFP. Several hypotheses could explain this discrepancy. First, the AAV transduction efficiency could not be the same between marmoset and *cynomolgus macaque*. Second, the vector promoter and injected dose were not the same as that used in our study design, leading to difficulties in comparing the results.[@bib42]

Brain transgene expression following LIT-KT injection represents an attractive strategy for the gene therapy of diseases that involve brain areas, such as Rett syndrome, Batten disease, or Pompe disease. We demonstrated that AAV9 ICV delivery allows specific GFP expression in MNs along the spinal cord; however, the percentage of transduced MNs was lower than that observed with the LIT-KT route. Regardless of the route of intra-CSF delivery, we noted that brain GFP expression was achieved mainly surrounding CD31-positive blood vessels ([Figure S7](#mmc1){ref-type="supplementary-material"}), as demonstrated by other groups.[@bib43]^,^[@bib44] Our observation supports the transport of vector from CSF to the brain parenchyma through the Virchow-Robin perivascular space.[@bib32]^,^[@bib45] In the brain, GFP expression mapping results are in line with previous studies that used intra-CSF delivery coupled to an AAV9-GFP vector in large animal models.[@bib22]^,^[@bib23]^,^[@bib28]^,^[@bib29]^,^[@bib31]^,^[@bib46]

In the present study, intra-CSF AAV administration leads to the targeting of predominantly large-diameter neurons in DRG along the spinal cord, and this observation is in line with a previous study that demonstrated large-diameter neuronal cells mainly transduced by using AAV5 and AAV8 in a mouse model.[@bib47] However, in our study, we did not observe substance P-positive transduced neurons into the NHP DRG, and this result is in contrast with the study of Vulchanova et al.[@bib47] This discrepancy could be due to the animal model and the AAV serotype that they used in this study.[@bib47] Neuronal DRG targeting following AAV9 and AAV7 ICM administration has previously been demonstrated in NHPs.[@bib32] Further investigations are needed to determine peptidergic and nonpeptidergic neuronal targeting by AAV9 and AAVrh10 following intra-CSF administration. Our study also demonstrates a particular specificity of the AAVrh10 serotype, which is to transduce mainly DRG neurons without MNs.

Another remarkable observation from our data was the ability of AAVrh10 and AAV9 serotypes to transduce skeletal and respiratory muscle fibers efficiently. We also found superior GFP expression in the heart for the AAV9 serotype following LIT-KT delivery, whereas similar GFP expression in the liver was achieved by the AAVrh10 serotype. Meyer and colleagues[@bib46] previously reported, in a detailed biodistribution study, that both viral genome and GFP mRNA were found in diaphragm, gastrocnemius, and triceps brachii muscles. Bevan and colleagues[@bib6] demonstrated that intravascular AAV9-CBA-GFP, at a dose of 1E+14 vg/kg in 1-, 30-, and 90-day-old NHPs, led to robust GFP expression in triceps brachii, diaphragm, and gastrocnemius muscles. They reported that the GFP pattern of expression in the same muscles was less abundant when the same vector was administered at a dose of 2.7E+13 vg/kg in 3-year-old monkeys,[@bib6] suggesting that systemic AAV delivery requires a 3-fold dose compared to the dose used for LIT-KT AAV9 delivery in the present study; however, it is difficult to make a strong correlation because of the heterogeneity in the method of titration of AAV vector preparation. Therefore, AAV9, harboring a ubiquitous CBA promoter, coupled to LIT-KT injection, represents an attractive strategy for the treatment of neuromuscular diseases, such as SMA and amyotrophic lateral sclerosis (ALS), and lysosomal storage diseases, such as Pompe disease, since single AAV9-CBA-GFP allows robust transgene expression in the CNS, respiratory muscle, skeletal muscle, and heart. Our results, in line with Meyer and colleagues,[@bib46] suggest peripheral AAV particle leakage from the CSF compartment to muscles and peripheral tissues. One mechanism that could explain the peripheral distribution of AAV is CSF absorption into the venous system.[@bib48] However, another hypothesis could be considered. In fact, AAV9 can travel along neuronal axons in both retrograde and anterograde manners,[@bib49]^,^[@bib50] and we cannot exclude AAV muscle targeting through nerve retrograde transport.

The kinetic serum shedding analysis revealed the presence of viral particles in serum at 1 h (which represented the higher concentration) and 3 days, whereas no AAV particles were detected in serum at 7 days postadministration. Additionally, we noted the superior persistence of AAV9 in the serum compared to that of AAVrh10 particles at 3 days post-LIT-KT delivery, which is in accordance with our previous study in mice.[@bib30]

Finally, one major aspect of AAV shedding into serum and peripheral organs that needs to be considered for clinical applications is the reaction of the immune system. All animals showed an increase in AAVrh10 and AAV9 serum NF starting on day 7, as also demonstrated by Hordeaux et al.,[@bib38] following AAV9 *cisterna magna* delivery. The direct consequence of NF anti-AAV protein capsids is the impossibility of redosing animals without strong immunosuppressive treatment, specifically by using systemic injection. However, at the time of euthanasia, our results revealed a relatively low NF concentration in CSF (1/100 titer) in 3/6 injected NHPs using the AAV9 serotype. As previously demonstrated by Gray and collaborators,[@bib22] blood-circulating AAV NFs at a titer of up to 1/128 had no inhibitory effect in CNS cell transduction following intra-CSF administration of an AAV9 in NHPs.

All of these immunological arguments could lead to multiple AAV redosing in the field of human intra-CSF gene therapy, but several preclinical study needs to be performed in order to demonstrate if peripheral NFs influence CNS cell transduction following AAV intra-CSF readministration. Currently, gene therapy is promising for treating patients affected by neurodegenerative diseases. However, there is a need to support long-term therapeutic efficacy by investigation of AAV readministration, specifically for infantile neurodegenerative diseases. Lastly, the results that we obtained through this study consolidate previous findings from other groups, showing that intra-CSF administration of AAV9 may the "gold standard" for clinical applications.

Taken together, these preclinical results support the safety and relevance of lumbar intrathecal using spinal catheter and ICV administration to deliver the AAV9 vector into the CNS and achieve efficient vector distribution and transgene expression in the brain and spinal cord. This study also provides evidence that neuron, MN, and glial cell transduction are superior with AAV9 compared to the AAVrh10 serotype. Furthermore, this study highlights that AAV intra-CSF injection represents a promising strategy for the gene therapy of neuromuscular disorders, due to this efficient respiratory and skeletal muscle targeting and transduction, combined with a significantly reduced AAV dose.

Materials and Methods {#sec4}
=====================

Animals {#sec4.1}
-------

Experiments were conducted on 2--3 kg male (2--4 years old), captive-bred *cynomolgus macaque* purchased from BioPrim (Baziège, France) or from Silabe (Strasbourg, France) and housed in the Boisbonne Center at Nantes Veterinary School (Oniris, Nantes, France). The experiments were approved by the Regional Ethics Committee and were carried out according to European guidelines for the care and use of experimental animals (authorization number CEEA.2011.29). We selected primates that had no detectable or low titers (\<1/50) of neutralizing factors against AAV serotypes 9 and 10 in the serum. All blood samples were collected under ketamine-induced anesthesia 10 mg/kg (Imalgene; Merial).

AAV Vectors {#sec4.2}
-----------

Vectors were generated by packaging AAV2-based recombinant sc genomes in AAV9 and AAVrh10 capsids by the helper virus-free transfection of HEK293 cells at the University Hospital of Nantes (<http://umr1089.univ-nantes.fr/>). The vectors were purified using an optimized cesium chloride gradient-based purification protocol, as previously described.[@bib20] The AAV2 plasmids contain the gene encoding the GFP under the control of a ubiquitous hybrid of the CBA and 4 repeated sequences of miR142. Physical particles were quantified by dot blot hybridization, and vector titers are expressed as vector genomes per milliliter.

*In Vivo* AAV Injections {#sec4.3}
------------------------

The animals were sedated with ketamine 10 mg/kg (Imalgene; Merial) and medetomidine 20 μg/kg, intubated, and anesthesia was continued by inhalation of 1% to 2% isoflurane in oxygen. Then, 1 to 1.5 mL of CSF was systematically removed before LIT-KT or ICV injection of AAV vectors. For LIT-KT administration, the animal was placed in lateral recumbence, and a catheter (pediatric epidural catheterization set, 25G + epidural needle 21G) was introduced via a SPROTTE cannula into the intrathecal space L3--L4. Placement was verified by the presence of CSF and real-time radioscopic examination. The catheter was slowly ascended to the cervical vertebrae under radioscopic control, and a solution of 1 mL of vector was then infused at a rate of 0.5 mL/min. The catheter was removed from 8 cm to be opposite of the thoracic vertebrae, and a new injection of 1 mL of vector was performed. The last deposit of 1 mL of vector occurred opposite of the first lumbar vertebrae and was followed by a flush of 0.4 mL of sterile saline. The needle was removed, and the animal was maintained in lateral recumbence for 1 h until recovery from anesthesia. The primates received 2.5E+13 vg of scAAVrh10-CBA-GFP or scAAV9-CBA-GFP.

For ICV administration, presurgical MRI was performed to establish brain coordinates. A small burr hole was made through the frontal bone, 20 mm caudally to the supraorbital arch and 2.5 mm laterally to the sagittal suture. A catheter (18G 1.3 × 32 mm) was introduced at a depth of 20 mm. The correct placement was verified by injecting 0.25 mL of contrast agent (Iopamiron; Bracco Imaging, France) under real-time radioscopic examination. Then, a solution of 0.5 mL of vector was infused at a rate of 0.1 mL/min, followed by a flush of 0.05 mL sterile saline. Primates received 4.5E+12 vg of scAAV9-CBA-GFP. A postsurgical MRI examination was performed to ensure the absence of neurologic lesions that could occur after ICV administration. The animal was then maintained in lateral recumbence until recovery from anesthesia. Throughout all surgical procedures, temperature, cardiac, respiratory frequency, capnography, pulse and electrocardiography were monitored.

The injected animals were immunosuppressed with sirolimus 2 mg/kg/day (Rapamune), prednisolone 1 to 2 mg/kg/day (Dermipred), and mycophenolate mofetil 40 mg/kg/day (CellCept) to avoid an immune response against AAV vectors and the transduced cells.

Clinical Follow-up {#sec4.4}
------------------

All injected primates were clinically evaluated before lumbar intrathecal or ICV injection and at 6 h and 1, 3, and 21 days thereafter. Animal behavior was evaluated using a video recording and a battery of cognitive, behavioral, neurological, and motor tests, following a protocol described by Ciron et al.[@bib20] After becoming habituated with the experimenter for 10 min, posture, gait, movements, behavior in response to auditory and visual stimulation, and fine motility were examined. Reflexes, temperature, heart frequency, and skinfold were evaluated after sedation with ketamine 10 mg/kg (Imalgene; Merial).

Tissue Collection and Processing {#sec4.5}
--------------------------------

3 weeks following vector delivery, the animals were anaesthetized (150 μg/kg medetomidine, 10 mg/kg ketamine, 0.2 mg/kg morphine, followed by 2% isoflurane inhalation), the spleen and inguinal lymph nodes were removed, and the animals were euthanatized by a perfusion of 100 mL of PBS and 400 mL 4% paraformaldehyde (PFA) in the carotid. The brain was placed on a monkey coronal brain matrix (Pelco, Redding, CA) and cut into 2-mm-thick coronal sections. Even slabs were postfixed by incubation in 4% PFA, cryoprotected, frozen on dry ice, and cryostat sectioned (10 μm) for morphological and immunohistochemical studies. Individualized cerebral structures of odd slabs were snap frozen in liquid nitrogen and then stored at −80°C for vg detection. The spinal cord was removed and cut into coronal 5-mm blocks, postfixed by incubation in 4% PFA, and cryoprotected by overnight incubation in 30% sucrose. The samples were then embedded in optimal cutting temperature compound, frozen on dry ice, and cryostat sectioned (10 μm). For vg detection, the ventral and dorsal parts of the cervical, thoracic, and lumbar spinal cord and the left and right DRG of these regions were snap frozen in liquid nitrogen and then stored at −80°C. The muscles, cranial, and peripheral nerves, liver, spleen, heart, kidney, and testis were also collected both for vg detection and morphological studies.

Assessment of GFP Fluorescent Signal Specificity {#sec4.6}
------------------------------------------------

The GFP signal was analyzed by using a spectral confocal microscope (LSM780; Karl Zeiss, Oberkochen, Germany). The Zeiss spectral system is able to record the fluorescence signals simultaneously every 9 nm on 34 separate detection channels, pixel by pixel, during scanning. With the use of this detection system, the autofluorescence signal was separated from the GFP fluorescence signal in the tissue. The autofluorescence spectrum was determined from the tissue sections of a noninjected NHP (negative control without GFP expression). The GFP spectrum was obtained from a GFP-positive cell of an AAV9-GFP-injected NHP with strong expression of GFP (positive control, Mac 3). By using autofluorescence, GFP reference spectra, and the Zeiss "Online Finger Printing" feature, the GFP fluorescence was separated from autofluorescence simultaneously during acquisition and as previously performed in our mice study.[@bib24]

Immunostaining and Motor Neuron Quantification {#sec4.7}
----------------------------------------------

Spinal cord and brain slices were examined for GFP expression using a laser-scanning confocal microscope. For ChAT immunofluorescence, the brain and spinal cord sections were blocked by incubation with 1% rabbit serum (Dako, Les Ulis, France) in 0.4% Triton X-100 in PBS and incubated overnight at room temperature with a goat polyclonal anti-ChAT antibody (1:100; Chemicon International, Temecula, CA, USA); the sections were then incubated with a biotinylated rabbit anti-goat antibody (Dako). For NeuN, GFAP, Olig2, and Iba1 immunostaining, the brain and spinal cord sections were incubated overnight at room temperature with antibodies directed against GFAP (Dako), Olig2 (Millipore, Billerica, MA, USA), and Iba1 (Wako), followed by a biotinylated rabbit anti-goat antibody (Dako). The sections were then incubated with Alexa Fluor 555-conjugated streptavidin (Life Technologies, Saint Aubin, France), mounted in Mowiol (Calbiochem, San Diego, CA), and scanned serially using an argon ion laser (488 nm) to observe GFP signals and a helium neon laser (543 nm) to observe Alexa Fluor 555 signals. Each image was recorded in a separated channel (green channel for GFP and red channel for Alexa Fluor 555) and overlaid for the detection of colocalized fluorescent signals. For MN counts, three serial 25 μm cryosections per animal and per cervical, thoracic, and lumbar spinal cord samples per animals, separated by 50 μm, were immunolabeled for ChAT and counterstained using Nissl (NeuroTrace; Molecular Probes, Life Technologies). The proportion of ChAT/GFP double-positive cells relative to the total number of MNs in the ventral horn was determined for each section using Fiji freeware (<https://fiji.sc/>).

Muscle Fibers and Peripheral Organ GFP Expression and Quantification {#sec4.8}
--------------------------------------------------------------------

The 10-μm-thick frozen-tissue sections (gastrocnemius, triceps brachii, diaphragm, heart, liver) were made by using cryostat (Leica). After 4% PFA fixation for 5 min and 3 × 5-min successive PBS baths, the slides were mounted using Mowiol mounting medium and observed under the spectral confocal microscope LSM 780 (Zeiss). For the quantification of GFP in skeletal muscle, diaphragm, heart, and liver, the microscopic fields were randomly selected to evaluate at least 1,000 cells for each peripheral organ explored using 20× magnification. Fiji freeware (<https://fiji.sc/>) was used for cell counting and area measurements.

Quantitative PCR Analysis {#sec4.9}
-------------------------

To analyze the number of AAV particles in the serum and CSF of the injected animals, the genome of AAV was extracted from the serum and CSF before and at different times post-injection using a nucleoSpin RNA virus kit (Macherey Nagel, Düren, Germany). GFP-specific real-time PCR was conducted in duplicate with the Thermocycler StepOne Plus System (Applied Biosystem) using 10 μL of extracted viral DNA in a 25-μL final volume of the following solution: 12.5 μL Premix ExTaq (TaqMan Fast Universal PCR Master Mix), 0.5 μL 10 μM primer, 0.125 μL 10 μM 6-carboxyfluorescein/tetramethylrhodamine (FAM/TAMRA) TaqMan probe, and 1.38 μL H~2~O. The cycle treshold (Ct) values were compared to those obtained with plasmid standard dilutions containing GFP cDNA sequences and a range of AAV particles mixed in the serum or CSF of noninjected NHPs. The primers and probes for GFP were as follows: forward primer 5′-ACTACAACAGCCACAACGTCTATATCA-3′, reverse primer 5′-GGCGGATCTTGAAGTTCACC-3′, probe 6FAM5′-CCGACAAGCAGAAGAACGGCATCA-3′-TAMRA; and ε-globin: forward primer 5′-TGGCAAGGAGTTCACCCCT-3′, reverse primer 5′-AATGGCGACAGCAGACACC-3′, probe 6FAM5′-TGCAGGCTGCCTGGCAGAAGC-3′-TAMRA. The samples were heated at 95°C for 20 s, followed by 40 cycles at 95°C for 3 s and 62°C for 30 s. Control tissues extracted separately from the vector-treated tissues were checked for GFP amplification. The sensitivity of the quantitative PCR is 10^−3^ copies/cell or 10 copies/50 ng of genomic DNA.

Detection of AAV9- and AAVrh10-Directed Neutralizing Factors {#sec4.10}
------------------------------------------------------------

AAV9- and AAVrh10-directed NFs were assessed in primate serum before and at 3 weeks following vector injection, as previously described in Guilbaud et al.[@bib51] Briefly, human wild-type adenovirus type 5 was incubated on a rAAV-permissive cell line for 2 h. Recombinant AAV9 or AAVrh10 expressing the LacZ product was incubated with 10-fold dilutions of biologic fluids (serum or CSF) and then added to Ad5 preinfected cells. After incubation for 24 h at 37°C and 5% CO~2~, the cells were fixed with 0.5% glutaraldehyde and then stained with X-Gal solution (Promega, Madison, WI, USA). The neutralizing factor titer was reported as the highest serum or CSF dilution that inhibited rAAV transduction (β-galactosidase expression) compared to the transduction control (rAAV without serum or CSF).
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[^1]: M, male; LIT-KT, lumbar intrathecal puncture using a transitory catheter; ICV, intracerebroventricular.

[^2]: NF, neutralizing factor; CSF, cerebrospinal fluid; d, day; dEuth, day of euthanasia; NA, not available sample.
